This study examines trends in aggregate use and expenditures for diabetes mellitus therapies among US Medicare Part D beneficiaries.
No takes yet. Share an insight, caveat, or question.
Sumarsono et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: